Bio Vitos Pharma

0.386

SEK

-19.42 %

BIOVIT

First North Stockholm

Medical Equipment & Services

Health Care

Be the first to follow this company

-19.42%

-51.26%

+206.35%

+208.8%

+62.18%

+34.49%

-73.59%

-85.37%

-92.14%

Bio Vitos Pharma operates in the medical technology industry. The company develops and commercializes products for the detection of hemolysis in blood samples. The company has developed products that ensure that the hemolysis is detected at an early stage, which means that the blood sample can be taken care of immediately. The company also develops digital reading that is used as a complement to the main product. Bio Vitos Pharma was founded in 2010 and is headquartered in Karlstad.

Market cap

15.21M SEK

Turnover

117.81K SEK

Revenue

3M

EBIT %

-430.67 %

P/E

-

Dividend yield-%

-

Financial calendar

14.2

2025

Annual report '24

13.5

2025

Interim report Q1'25

14.5

2025

General meeting '24

ShowingAll content types

Regulatory press release11/13/2024, 2:15 PM

Bio Vitos Pharma AB (publ) appoints LAGO KAPITAL as liquidity provider

Bio Vitos Pharma

Regulatory press release2/12/2024, 12:50 PM

Bio Vitos Pharma AB: KFUM Kalmar and Bio Vitos Pharma enter into an agreement regarding a research study on Succifer

Bio Vitos Pharma

Regulatory press release12/20/2023, 6:30 AM

Bio Vitos Pharma AB: The European Patent Office EPO grants patent that is important to Bio Vitos Pharma

Bio Vitos Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release10/20/2023, 2:20 PM

Hemcheck completes the transaction with Bio Vitos

Bio Vitos Pharma

Regulatory press release5/15/2023, 1:20 PM

Hemcheck has received a first order from its distributor Astemed

Bio Vitos Pharma

Regulatory press release5/4/2023, 12:00 PM

Hemcheck submits a formal application to Nasdaq for a decision on continued listing before the implementation of the Bio Vitos agreement

Bio Vitos Pharma

Regulatory press release4/26/2023, 2:20 PM

Hemcheck: Additional follow up order from the Foundation for Innovative New Diagnostics (FIND)

Bio Vitos Pharma

Regulatory press release4/5/2023, 8:50 PM

Hemcheck has received a first order from the university hospital Charité in Berlin

Bio Vitos Pharma

Regulatory press release3/16/2023, 12:10 PM

Hemcheck: Additional agreement with Bio Vitos Medical brings forward the time for calling the extraordinary general meeting by one week

Bio Vitos Pharma

Regulatory press release3/13/2023, 4:00 PM

Hemcheck has received a first follow up order from its Finnish distributor

Bio Vitos Pharma

Regulatory press release3/2/2023, 4:00 PM

Hemcheck has received an additional follow up order from its UK distributor

Bio Vitos Pharma

Regulatory press release2/28/2023, 8:15 PM

Hemcheck receives follow up order from research program in the United States

Bio Vitos Pharma

Regulatory press release2/3/2023, 3:30 PM

Hemcheck has received a follow up order from its French distributor

Bio Vitos Pharma

Regulatory press release2/1/2023, 1:30 PM

Hemcheck has received a follow up order from its UK distributor

Bio Vitos Pharma

Regulatory press release1/24/2023, 4:00 PM

Hemcheck has received a first order from a leading hospital in Iceland

Bio Vitos Pharma

Regulatory press release1/23/2023, 10:00 AM

Hemcheck has received a follow up order from its Spanish distributor

Bio Vitos Pharma

Regulatory press release1/16/2023, 9:30 PM

Hemcheck has received another follow up order from its Irish distributor

Bio Vitos Pharma

Regulatory press release1/3/2023, 4:27 PM

Hemcheck extends agreement regarding previously communicated project with Region Skåne

Bio Vitos Pharma

Regulatory press release12/20/2022, 9:00 AM

Hemcheck has received a follow up order from its Irish distributor

Bio Vitos Pharma

Regulatory press release12/12/2022, 2:00 PM

Hemcheck has received an important order from a major OEM

Bio Vitos Pharma

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.